IL-18 is likely to contribute to asthma. However, little is known regarding the role of IL-18 binding protein (BP) and IL-18 receptor (R) in asthma. Because the action of IL-18 in the body is regulated by IL-18BP and mast cells and basophils are key cell types involved in asthma, we investigated the expression of IL-18, IL-18BP and IL-18R in basophils and mast cells using flow cytometry and a mouse asthma model. We found that among basophils, approximately 53% and 51% were IL-18 + , 85% and 81% were IL-18BP + basophils, and 19.8% and 8.6%
| INTRODUCTION
IL-18 is a pleiotropic proinflammatory cytokine that plays a key role in both innate and acquired immunities. IL-18 variants are significantly associated with asthma severity, 1 and IL-18 protein and IL-18R are upregulated in the lungs of patients with asthma, 2 implicating IL-18 in asthma pathogenesis. Furthermore, low levels of IL-18 were observed in the sputum of patients with asthma 3 and in the sputum supernatant of patients with severe refractory asthma, 4 which correlates with the number of macrophages and inversely correlates with the percentage of neutrophils, but does not correlate with eosinophil cationic protein (ECP) and eosinophils. 4 To clarify the potential role of IL-18 in asthma, we examined the expression of IL-18, IL-18BP and IL-18R in blood basophils and sputum mast cells in this study. IL-18BP is an endogenous antagonist with high neutralizing capacity that inhibits the action of IL-18 by preventing its interaction with cell surface receptors. 5 A molar excess of 10 of IL-18BP over IL-18 is required to decrease a pathological level of 400 pg/mL of IL-18 to the level of an HC subject (40 pg/mL). 6 It is possible that an imbalance between IL-18 and IL-18BP might account for increased IL-18 activity in asthma. We therefore chose to investigate the influence of IL-18 on the expression of IL-18BP and IL-18R in blood basophils and lung mast cells. It has been reported that Alternaria extract induces the rapid release of IL-18 from cultured normal human bronchial epithelial cells and directly initiates Th2 differentiation of na€ ıve CD4 + T cells via a unique NF-jB-dependent pathway. 7 Furthermore, IL-18 has been linked to the induction of IL-13 production in mast cells and basophils, 8 suggesting that allergens may trigger airway reactions via IL-18 and that IL-18 may affect the function of mast cells and basophils. Because mast cells and basophils are key cell types involved in asthma 9 that produce an array of cytokines, 10 they could be a major source of IL-18. We therefore examined the potential contribution of mast cells and basophils to asthma via IL-18-, IL-18BP-and IL-18R-associated mechanisms. The aim of this study was to further investigate the role of IL-18-related mechanisms in the pathogenesis of asthma.
| MATERIALS AND METHODS

| Reagents
The following reagents were purchased from Biolegend (San Diego, USA): PerCP/Cy5.5-conjugated mouse antihuman CCR3, Brilliant Violet (BV)421-conjugated mouse anti-human CD123, APC/Cy7-conjugated mouse antihuman HLA-DR, PE/Cy7-conjugated mouse anti-human CD34, PerCP/Cy5.5-conjugated mouse anti-human FceRIa, PerCP/Cy5.5-conjugated rat anti-mouse CD49b, PE-conjugated rat anti-mouse FceRIa, PerCP/Cy5. 
| Subjects and animals
A total of 31 patients with asthma and 14 HC subjects were recruited in the study. Their general characteristics and diagnostic criteria were previously described.
11
Informed consent was obtained from each volunteer according to the declaration of Helsinki in agreement with the ethical committee of the General Hospital of Shenyang Military Region of PLA, with the Second Affiliated Hospital of Shenyang Medical College or with the First Affiliated Hospital of Jinzhou Medical University. The procedure for collecting and treating peripheral blood specimens was described previously. 11 For certain patients, sputum was collected immediately after admission (during the acute exacerbation stage). BALB/c mice (6-7 w, 18-22 g) were obtained from Vital River Laboratory Animal Technology Co., Ltd. (Beijing, China) under Certificate No. 11400700118761 and were bred and reared under strict ethical conditions approved by the Animal Care Committee at Jinzhou Medical University.
5 mL sputum was collected from each patient. After mixing with a fourfold volume of 0.1% dithiothreitol for 15 minutes, the suspended sputum was centrifuged. The supernatant was stored at À80°C until use, and the cell pellet was resuspended in PBS for flow cytometry analysis as described below. Cells were incubated in the presence of 2 lg/mL brefeldin A for 1 hour at 37°C. Each labelled monoclonal antibody, including PerCP/Cy5.5-conjugated anti-human CCR3, BV421-conjugated anti-human CD123, APC/Cy7-conjugated anti-human HLA-DR and APC-conjugated antihuman IL-18Ra, was added into the tube. After fixation and permeabilization by the Cytofix/Cytoperm TM Fixation/ Permeabilization Kit, the cells were incubated with PE-conjugated anti-human IL-18 and anti-human IL-18BP primary antibodies before the addition of BV510-conjugated donkey anti-rabbit polyclonal antibody for 30 minutes. Finally, the cells were resuspended in fluorescence-activated cell sorting (FACS)-Flow solution and were analysed with a FACSVerse flow cytometer (BD Biosciences, San Jose, CA). A total of 10 000 events in a live cell gate were analysed for each sample. The data were analysed with FLOWJO software, version 7.0 (Treestar, Ashland, USA). Dead cells and doublets were excluded from the analysis by live/dead cell dyes.
|
To detect the expression of IL-18, IL-18BP and IL-18R in sputum mast cells isolated from patients with asthma, dispersed cells were incubated with human Fc receptor blocking solution and a live/dead cell dye (Zombie Green TM Fixable Viability Kit) 14 for 15 minutes before the addition of PE/Cy7-conjugated anti-human CD34, PerCP/Cy5.5-conjugated anti-human FceRIa, BV421-conjugated mouse anti-human CD117 and APC-conjugated anti-human IL18Ra antibodies to the tube. Cells were then permeabilized, processed following human blood sample protocols and analysed by flow cytometry.
| Mouse sensitization and challenge
Mice were sensitized and challenged with an OVA solution following a procedure described previously. 11 Normal saline (1 mL) containing 1 mmol/L EDTA was infused into the unilateral lung for 2 minutes before the animals were sacrificed and their bronchoalveolar lavage fluid (BALF) collected. Blood samples were collected by enucleation of the eyeball and were centrifuged at 450 g for 10 minutes. The cells were used for flow cytometric analysis, and plasma was collected and frozen at À80°C until further use.
| Dispersion of mouse lung cells
Lung tissues were excised and digested into single cells as described previously. 15 16 and anti-mouse CD16/32 as described above before the addition of APC/ Cy7-conjugated anti-mouse Ly6C, PE-conjugated antimouse FceRIa, PerCP/Cy5.5-conjugated anti-mouse CD49b and APC-conjugated anti-mouse IL-18R antibodies to the tube for 15 minutes. The resuspended cells were then fixed and permeabilized using a Cytofix/ Cytoperm TM Fixation/Permeabilization kit, followed by the addition of FITC-conjugated anti-mouse IL-18BP antibody for 30 minutes. Finally, the cells were processed and analysed as described above.
To detect the expression of IL-18BP and IL-18R by mast cells of mouse BALF and lung tissues, the cells were incubated with anti-mouse CD16/32 for 15 minutes before the addition of PE-conjugated anti-mouse FceRIa, PerCP/Cy5.5-conjugated anti-mouse CD117 and APC-conjugated anti-mouse IL-18R antibodies to the tube. After incubating at room temperature for 15 minutes, the cells were fixed and FITC-conjugated antimouse IL-18BP antibody was added. The flow cytometer analysis procedure used was as same as for human cells.
| Determination of IL-18BP level in mouse plasma
The level of IL-18BP in mouse plasma was detected by sandwich ELISA. A polyclonal anti-mouse IL-18BP antibody was used as the capture antibody, and a biotinylated anti-mouse IL-18BP antibody was employed as the detection antibody. A recombinant mouse IL-18BP was used as a standard. The detection range of the standard curve was 7.8-125 ng/mL.
| Statistical analysis
Statistical analyses were performed using SPSS software (Version 17.0; IBM Corporation). The plasma levels of IL-18BP as well as data for the expression of IL-18, IL-18BP and IL-18R in basophils and mast cells are displayed as boxplots indicating the median, interquartile range, and largest and smallest values for the number of experiments indicated. Where Kruskal-Wallis analysis indicated significant differences between groups for preplanned comparisons of interest, the paired Mann-Whitney U test was employed. For all analyses, P < .05 was taken as significant.
| RESULTS
| Enhanced number of basophils in peripheral blood of patients with atopic asthma
Increased plasma levels of IL-18 17 and expression of IL-18R
by inflammatory cells 18 in asthma patients have been reported.
However, the source of increased plasma IL-18 in asthma remains to be determined, and the expression levels of IL-18BP and IL-18R in the basophils of asthma patients are unknown. We therefore examined the expression levels of IL-18, IL-18BP and IL-18R in basophils isolated from the blood of patients with asthma. Our results showed that the proportion of basophils (0.45%) in asthmatic blood was much greater than that observed in the blood of HCs (0.14%). We found that approximately 53% and 51% of basophils in HC and asthmatic blood, respectively, expressed IL-18, and more than 85% and 81% of basophils in HC and asthmatic blood, respectively, expressed IL-18BP. However, only 19.8% and 8.6% of basophils in HC and asthmatic blood, respectively, expressed IL-18R ( Figure 1B ,C), representing a 56.4% reduction in IL-18R + basophils in asthmatic blood compared with HC blood. The allergens tested had little effect on IL-18, IL-18BP and IL-18R expression in basophils (data not shown). In terms of MFI, basophils expressed a high density of IL-18BP and much lower densities of IL-18 and IL-18R. Furthermore, asthmatic basophils appeared to express less IL-18BP than HC basophils ( Figure 1D ,E).
| Expression of IL-18, IL-18BP and IL-18R by sputum mast cells obtained from asthma patients
In contrast to plasma, 17 the level of IL-18 in asthmatic sputum seemed to be lower than that in HC sputum. 3 Because mast cells are one of the key cell types involved in asthma 9 and produce an array of cytokines, 10 they could be a major source of IL-18. (Figure 2A,B) , and only 3.5%, 14.3% and 2.4% of these cells expressed IL-18 ( Figure 2C ), IL-18BP ( Figure 2D ) and IL-18R ( Figure 2E ), respectively, in asthmatic sputum.
| Altered IL-18BP and IL-18R expression in basophils following sensitization and IL-18 treatment
To further understand the action of IL-18 in asthma, we examined the effect of IL-18 on IL-18BP and IL-18R expression in blood basophils obtained from OVA-sensitized mice. We found that sensitization enhanced the number of basophils present in mouse blood ( Figure 3A 
| Altered expression of IL-18BP and IL-18R in mast cells of BALF by sensitization and IL-18
It is difficult to obtain permission to collect bronchoalveolar lavage fluid (BALF) for experimental purposes from patients with asthma. We therefore investigated the influence of IL-18 on the expression of IL-18BP and IL-18R by BALF mast cells of sensitized mice. We found that sensitization and IL-18 increased the number of mast cells in BALF ( Figure 4A 
| Enhanced levels of IL-18BP in mouse plasma
To examine the influence of sensitization and IL-18 on IL-18BP production, we investigated the effects of OVA and IL-18 on IL-18BP plasma level in mice. We found that OVA sensitization decreased plasma IL-18BP level in comparison with non-sensitized mice. IL-18 injection increased the plasma IL-18BP levels of non-sensitized and OVA-sensitized mice by 48.0% and 16.1%, respectively ( Figure 6 ).
| DISCUSSION
The current study clearly demonstrates that the number of basophils increases in the peripheral blood of patients with asthma and in the blood of OVA-sensitized mice, suggesting that basophils are likely to participate in asthma pathogenesis. Because the involvement of basophils in asthma has long been recognized, 19 our finding could be important for understanding asthma pathogenesis. We found that greater than 50% and 80% of human peripheral blood basophils express IL-18 and IL-18BP, respectively, regardless of A Gating strategy of basophils in mouse blood leucocytes, and IL-18BP and IL-18R expressing basophils. Data are displayed as a boxplot for sensitized (AM, n = 7) and healthy (HM, n = 6-7) mice, which indicates the median, interquartile range, the largest and smallest values for the number of animals indicated. AF, all fluorescence; FMO, fluorescence minus one. P < .05 was taken as significant (paired Mann-Whitney U test)
blood by approximately 47.8%; on the other hand, it caused a 16.1% increase in the level of plasma IL-18BP. These findings suggest that the IL-18-induced increase in plasma IL-18BP level is unlikely to be mediated by basophils. Because the expression of IL-18, IL-18BP and IL-18R by asthmatic basophils was previously uncharacterized, our observations provide novel insight into the relationship between IL-18, basophils and asthma pathology. Contradictions between the human and mouse models were observed in this study. For example, more than 80% of human blood basophils, but only 22.7% of mouse blood basophils, express IL-18BP in asthma models. Furthermore, almost all mouse basophils express IL-18R, but only 8.6% of basophils in human asthmatic blood expressed IL-18R. These findings add more information to the controversy over the function of murine and human basophils in allergic inflammation 20 and suggest once again the limitation of animal models in studying human diseases. Obviously, further work is required to address these issues. We also found only 3.5%, 14.3% and 2.4% of mast cells in asthmatic sputum expressed IL-18, IL-18BP and IL-18R, respectively. The low proportion of IL-18-expressing mast cells and the fact that only 0.39% of mast cells in sputum were nucleated suggests that mast cells are unlikely to be Percentage of basophils in mouse blood leucocytes, and expressions of IL-18BP and IL-18R in basophils.
the primary source of IL-18 in asthmatic sputum, which may help to explain the low level of IL-18 present in the sputum of patients with asthma.
3 Extrinsic IL-18 elicited an increase in mast cell number in the BALF of OVA-sensitized mice of approximately 6%, suggesting that IL-18 might play a role in asthma via mast A Gating strategy of mast cells in mouse BALF, and IL-18BP and IL-18R expressing mast cells.
cells. Although we lack data regarding the mechanism of IL-18-mediated mast cell migration, the finding that IL-18 attracts plasmacytoid dendritic cells (DC2s) through IL-18R expression 21 suggests that IL-18-induced mast cell accumulation acts via its ability to upregulate the expression of IL-18R on mast cells. Because mast cells can release proinflammatory mediators such as prostaglandin D2, leukotriene C4, platelet activation factor 9 24 we believe that IL-18 may play a role in asthma. respectively, in response to IL-18 or NS. Data are displayed as a boxplot for sensitized (AM, n = 7) and healthy (HM, n = 6-7) mice, which indicates the median, interquartile range, the largest and smallest values for the number of animals indicated. FMO, fluorescence minus one. P < .05 was taken as significant (paired Mann-Whitney U test)
In conclusion, a large proportion blood basophils from patients with asthma express IL-18 and IL-18BP, a dramatic increase in IL-18R+ basophils is observed in OVA-sensitized mouse blood, and extrinsic IL-18 enhances mast cell as well as IL-18R+ mast cell numbers in the BALF and lung tissue of OVA-sensitized 
CONFLICT OF INTEREST
The authors declare that there is no competing interest regarding the publication of this article. injection of normal saline (NS) and IL-18, plasma of healthy mice (HM) and sensitized mice (SM) was taken, and analysed using a sandwich ELISA. Data are displayed as a boxplot for sensitized (AM, n = 7) and healthy (HM, n = 6-7) mice, which indicates the median, interquartile range, the largest and smallest values for the number of animals indicated. P < .05 was taken as significant (paired Mann-Whitney U test)
